10-Q Summary
Filing and period: The provided filing is for DanDrit Biotech USA, Inc., not Lunai Bioworks Inc. It reports the quarter and nine months ended March 31, 2016, compared with the comparable periods ended March 31, 2015. The request metadata identifies “2015 Q3,” which does not match the filing period.
Business context
DanDrit is a biopharmaceutical company developing dendritic-cell cancer vaccines, principally MelCancerVac (MCV) for colorectal cancer. Its Danish subsidiary conducts research, development, manufacturing and clinical activities. MCV sales remain limited primarily to compassionate-use programs in Singapore and are not approved for general sale elsewhere.
Financial results and position
| Metric | Three months ended March 31, 2016 | Nine months ended March 31, 2016 |
|---|---|---|
| Revenue | $0 | $42,525 |
| Gross profit | $0 | $37,281 |
| Operating expenses | $513,604 | $1,487,220 |
| Loss from operations | $(513,604) | $(1,449,939) |
| Net loss | $(207,563) | $(979,641) |
| Loss per share | $(0.02) | $(0.10) |
- Research and development expense was $235,927 for the quarter and $615,334 for the nine months, primarily related to the Phase III MCV clinical trial.
- Other income was $272,233 for the quarter and $72,474 for the nine months, driven primarily by currency transaction gains.
- Cash was $151,222 at March 31, 2016, down from $421,145 at June 30, 2015. Cash held in escrow declined from $1,052,989 to zero.
- Total assets were $980,515, compared with $2,072,877 at June 30, 2015. Current liabilities were $1,043,906, resulting in a working-capital deficit of approximately $208,820.
- Related-party notes payable totaled $102,712, all classified as current. Accounts payable and accrued expenses totaled $910,271.
- Stockholders’ equity declined to a deficit of $(63,391) from $1,077,140 at June 30, 2015.
- Cash used in operating activities for the nine months was $1,162,022. Investing activities provided $1,052,989, primarily from release of escrowed cash, while financing activities provided no cash.
Material changes versus the prior comparable period
- Nine-month revenue increased from $0 to $42,525, primarily from a final payment on the Naimet project and a smaller Singapore lysate sale.
- Nine-month gross results improved from a $258,278 loss to $37,281 of profit because of the Naimet payment and lower cost of goods sold.
- Quarterly and nine-month operating expenses decreased 37% and 28%, respectively, largely because of lower legal, audit, consulting and equity-financing-related costs.
- Research and development expense increased substantially, from $151,813 to $615,334 for the nine-month period, reflecting Phase III clinical-trial activity.
- Nine-month net loss improved 64%, from $2,741,719 to $979,641. The improvement also reflected currency gains in 2016 versus currency losses in 2015.
- Operating cash burn improved from $3,435,986 to $1,162,022, but the company ended the period with materially reduced liquidity and no financing cash inflows.
Outlook, risks and unusual items
- Management states that recurring losses, a working-capital deficit and insufficient funds for projected losses and planned Phase III testing raise substantial doubt about the company’s ability to continue as a going concern.
- The company expects to seek additional capital through equity sales, shareholder loans or commitments, and future compassionate-use product sales. Two $1 million capital commitments were reported, each expiring July 10, 2016.
- Management believes available cash and potential funding sources may support the next twelve months, but acknowledges that financing may not be available on acceptable terms or at all.
- MCV requires extensive regulatory and clinical approvals, and the filing states that FDA approval and commercially sufficient revenues cannot be assured.
- On April 4, 2016, the company entered into an agreement to acquire certain OncoSynergy assets and liabilities. The transaction is subject to shareholder approval, other conditions and at least $3 million of equity capital for each party. OncoSynergy would receive consideration resulting in approximately 50% ownership of the combined company on a fully diluted basis, subject to closing conditions.
- The company reported no material pending legal proceedings, no material off-balance-sheet arrangements and effective disclosure controls as of March 31, 2016.
Important facts for investors to verify
- Confirm the issuer and reporting period, since the supplied metadata does not match the filing.
- Assess the going-concern disclosure against cash of $151,222, the working-capital deficit and upcoming debt and operating obligations.
- Verify the status, enforceability and expiration of the two reported $1 million capital commitments.
- Review the Phase III MCV trial scope, spending requirements, regulatory status and probability of commercialization.
- Evaluate the proposed OncoSynergy transaction, including required financing, shareholder approval, dilution and closing deadline of October 31, 2016.
- Consider the effect of currency gains and losses on reported earnings and comprehensive income.